XBIO-020: DNase I Armored CAR T Targeting Solid Tumors
CAR T therapies have demonstrated to be effective against hematological malignancies, such as leukemia and lymphoma. However their use in solid tumors has been limited by a number of factors, including tumor heterogeneity, the immunosuppressive tumor microenvironment and Tumor Escape Mechanisms.
We are developing XBIO-020, a DNase I to be delivered to the tumor and secreted by CAR T therapies. While maintaining CAR T cell tumor killing function, DNase digests DNA and NETs in the tumor microenvironment, thereby facilitating tumor access to the CAR T therapy.Learn More About NETs and Their Roll as a Driver of Cancer Progression and Metastasis and How They Can Contribute to Resistance to Cancer Therapies